MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
15 mai 2019 17h07 HE
|
MacroGenics, Inc.
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy)Oral abstract will be presented at American...
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results
01 mai 2019 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, Md., May 01, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call
24 avr. 2019 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019
03 avr. 2019 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 03, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
02 avr. 2019 17h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...